Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis

Abstract

Background: Insomnia is a multi-factorial disorder with conventional treatment options that are not satisfactory for many patients. This metaanalysis analyzed the safety and efficacy of daridorexant.

Methods: An electronic database search for RCTs was conducted on Medline via PubMed, Cochrane, and Clinicaltrials.gov using the terms 'Daridorexant,' 'RCT,' 'Insomnia' trials evaluating the efficacy and/or safety of daridorexant for insomnia were included. The data were synthesized using Cochrane review manager version 5.4.1. Cochrane risk of bias 2.0 tool and GRADEpro-GDT were used to assess the methodological and evidence quality, respectively.

Results: Of 109 searched studies, four trials were included. The risk of treatment-emergent adverse events with 25 mg daridorexant [risk ratio (RR) = 1.12 (0.88, 1.43), p = 0.36; I² = 0%] and 50 mg daridorexant [RR = 1.25 (0.88, 1.79), p = 0.22; I² = 28%] and serious adverse events with 25 mg [RR = 0.86 (0.23, 3.19), p = 0.82, I² = 56%] and 50 mg [RR = 1.32 (0.29, 6.08), p = 0.72, I² = 52%] was comparable to placebo [Moderate quality evidence]. Risk of nasopharyngitis was also comparable to placebo. The efficacy parameters like wake after sleep onset, latency to persistent sleep, and subjective total sleep time showed significant improvement with daridorexant. The risk of bias is low for three studies and some concern for one.

Conclusion: Daridorexant is a safer and efficacious agent for induction and maintenance of sleep for chronic insomnia.

Prospero: The registration number is CRD42022335233.

Clinical trial registration: www.clinicaltrials.gov identifiers are NCT03575104, NCT03545191, NCT03679884, and NCT02839200).

Keywords: Daridorexant; Serious adverse events; adverse events; dual orexin receptor antagonist; insomnia; orexin.